Why Buy CINGAL® from Kinami Health

Kinami Health makes it simple for Canadian clinics, orthopaedic specialists and licensed professionals to order CINGAL® online from a trusted wholesale supplier, with every product sourced through verified channels for professional use.

When you buy CINGAL® from Kinami Health, you benefit from:

• Genuine CINGAL® products from verified supply channels
• Wholesale pricing for professional clinic orders across Canada
• Fast, reliable delivery for orthopaedic practices
• Access to related orthopedic injections for broader treatment planning

CINGAL® is especially valuable for clinics that want a single-injection option combining the immediate relief of a corticosteroid with the lubricating benefit of hyaluronic acid.

CINGAL® – The Dual-Action, Single-Injection Advantage

CINGAL® is unique among the viscosupplements in this range because it is a combination product. Each 4 mL single-dose syringe contains 88 mg of hyaluronic acid and 18 mg of triamcinolone hexacetonide – a corticosteroid. The corticosteroid targets inflammation for fast, early symptom relief, while the cross-linked hyaluronic acid supports joint lubrication over the following months. The full treatment is delivered in one intra-articular injection by a qualified healthcare professional.

CINGAL® vs Monovisc, Orthovisc, Durolane & Cortisone

When comparing CINGAL® with other knee osteoarthritis treatments, the defining difference is its dual-action formulation. Monovisc offers a single-injection, high-dose hyaluronic acid protocol but without the corticosteroid component that provides immediate relief. Orthovisc is a multi-injection viscosupplement, typically requiring three weekly appointments – less convenient than CINGAL®’s single injection. Durolane offers a single injection based on NASHA technology, but again without the dual mechanism that addresses both immediate and longer-term symptoms.

Compared with a standard cortisone injection, which gives quick relief from inflammation but no lubricating benefit, CINGAL® adds the longer-term joint-lubrication effect of hyaluronic acid. In North America, where Synvisc and cortisone are familiar reference points, CINGAL® is often positioned as the single-visit option that does both.

How CINGAL® Works & How Long Relief Lasts

CINGAL® works on two timelines. The triamcinolone hexacetonide component reduces inflammation quickly after injection, targeting early osteoarthritis pain. The cross-linked hyaluronic acid then supplements the synovial fluid, supporting lubrication and cushioning in the knee joint over the months that follow.

Because it combines both mechanisms, CINGAL® is designed to provide relief from the first days after injection and to sustain it. Individual results vary with the patient, severity of osteoarthritis, injection technique and treatment plan, and expected duration should be discussed with the treating professional.

Administering Techniques

Proper administration of CINGAL® requires precise intra-articular injection into the synovial space. In Canada, who may administer intra-articular injections varies by province and professional college, so practitioners should follow the rules that apply in their own jurisdiction. General considerations include:

• Use a sterile, disposable hypodermic needle (typically 18-21 gauge)
• Consider ultrasound guidance for accurate placement if necessary
• Maintain strict aseptic technique throughout the procedure
• Avoid injection into blood vessels, surrounding tissues or extra-articular structures
• Ensure the treatment area is clean and free of infection before injection
• Advise patients to rest the treated joint for 24-48 hours post-injection

Side Effects & Safety

While generally well tolerated, potential side effects of CINGAL® may include transient pain, swelling or discomfort at the injection site that typically resolves within days; temporary joint stiffness or a heat sensation that subsides quickly; and, rarely, rash, itching or bruising at the injection site. Some patients may experience skin thinning or discolouration at the injection site.

If patients experience persistent or severe reactions, they should contact their healthcare provider immediately. In Canada, adverse reactions can be reported to Health Canada.

CINGAL® Product Range

CINGAL® 4 mL – a single-dose syringe containing 88 mg of hyaluronic acid and 18 mg of triamcinolone hexacetonide, designed for standard knee osteoarthritis treatment by intra-articular injection.